Can You Take Mushrooms on SSRIs? What to Know

Psilocybin mushrooms taken alongside SSRIs are unlikely to cause serotonin syndrome, but the SSRI will probably weaken the mushroom experience considerably. A large survey-based study found that roughly half of people who took psilocybin mushrooms while on an SSRI reported weaker-than-expected effects. The interaction is less about acute danger and more about the SSRI quietly undermining what psilocybin does in the brain, and that blunting effect can persist for months after stopping the antidepressant.

Why SSRIs Dampen the Mushroom Experience

Psilocybin works by binding to a specific serotonin receptor called 5-HT2A. That receptor is the main target for the psychedelic experience. SSRIs, by flooding the synapse with extra serotonin over weeks and months, cause the brain to adapt by turning down the sensitivity of those same receptors. Animal research confirms this: in mice given fluoxetine (the active ingredient in Prozac) for two weeks, the behavioral response to a psychedelic compound was significantly reduced, while a single acute dose of the same SSRI had no such blunting effect.¹ This lines up with research showing that chronic SSRI treatment desensitizes 5-HT2A receptors as a downstream consequence of keeping serotonin levels elevated for a prolonged period.²

In practical terms, this means that a person who has been taking an SSRI for several weeks or longer has fewer responsive 5-HT2A receptors available for psilocybin to activate. The mushrooms still get metabolized into psilocin (the active compound), and psilocin still reaches the brain, but the lock it is trying to turn has been partially changed. The result for most people is a muted, underwhelming, or entirely absent psychedelic experience.

How Often the Effects Are Weakened

The clearest data on this comes from a study that analyzed over 600 reports from people who took psilocybin mushrooms while on an antidepressant. Among those on SSRIs, about 47% reported weaker-than-expected effects. For people on SNRIs (a related class that also boosts serotonin), the number was even higher, around 55%. By comparison, only about 29% of people taking bupropion, an antidepressant that does not primarily target serotonin, reported weakened effects.³ That gap between serotonergic and non-serotonergic antidepressants strongly suggests the blunting is driven by what the SSRI is doing to serotonin receptors, not just by some general pharmacological interference.

Worth noting: about half of the SSRI users still reported a noticeable experience. The blunting is not all-or-nothing. Some people on SSRIs describe a somewhat weakened trip, others feel almost nothing, and a smaller group reports something closer to a normal experience. The variation likely depends on the specific SSRI, the dose, how long someone has been taking it, and individual biology. But the overall trend is clear, and researchers studying psilocybin as a treatment for depression have increasingly had to grapple with whether participants need to stop their SSRIs first.

Is the Combination Physically Dangerous?

The fear most people have is serotonin syndrome, a potentially life-threatening condition caused by excessive serotonin activity. This concern makes intuitive sense: SSRIs raise serotonin, and psilocybin acts on serotonin receptors. But the pharmacology is more nuanced than “more serotonin equals danger.” Serotonin syndrome typically requires either a massive serotonin overdose or the combination of a serotonin-boosting drug with a monoamine oxidase inhibitor (MAOI), which prevents the body from breaking serotonin down. Serotonergic drugs that do not involve MAOIs are considered low-risk when combined with psychedelics that also do not contain MAOIs.⁴

A 2025 scoping review that pulled together ten studies evaluating the safety of combining antidepressants with classic psychedelics found no cases of serotonin toxicity or serotonin syndrome. This held true across studies involving SSRIs, SNRIs, tricyclics, and even MAOIs in some older investigations.⁵ The evidence here is reassuring, though it comes mostly from controlled research settings rather than unsupervised recreational use. In a clinical trial, doses are measured, medical staff are present, and participants are screened for other medications. Street use involves more variables and less control, so the safety profile in research does not guarantee the same safety profile outside of it.

That said, the current body of evidence does not support the idea that taking psilocybin mushrooms on an SSRI is a recipe for serotonin syndrome. The combination’s primary risk is not toxicity. It is futility: spending the experience feeling underwhelmed and then wondering whether something went wrong.

MAOIs Are a Genuinely Dangerous Exception

The safety picture changes dramatically when you swap SSRIs for MAOIs, an older and less commonly prescribed class of antidepressant. A published case report describes a 42-year-old man with treatment-resistant depression who took just one gram of psilocybin mushrooms while prescribed tranylcypromine (an MAOI) and extended-release amphetamine. Within about half an hour, he developed a hypertensive emergency with severe chest pain, palpitations, and headache.⁶ That reaction was acute and dangerous in a way that SSRI-psilocybin interactions generally are not.

MAOIs prevent the breakdown of monoamines, including serotonin, norepinephrine, and dopamine. When psilocybin adds another hit of serotonin receptor activation on top of that, and especially when stimulant medications are also in the mix, the result can overwhelm the body’s ability to regulate blood pressure and heart function. If you are on an MAOI, psilocybin mushrooms are a genuinely risky combination, not a “probably blunted” one.

The Tapering Problem

Because SSRIs blunt psilocybin’s effects, people interested in psilocybin therapy (and some recreational users) face a tempting idea: just stop the SSRI first. This is where things get complicated, because stopping an SSRI is itself medically significant. Antidepressant discontinuation can trigger withdrawal symptoms like dizziness, irritability, brain zaps, and insomnia. More importantly, it can cause a rebound in depression symptoms.

One study tracked participants who discontinued serotonergic antidepressants before entering a psilocybin trial and found that their depression scores worsened between screening and the trial’s baseline. Compared to participants who entered the trial already off antidepressants, those who tapered showed meaningful increases in symptom severity during the tapering period.⁷ That worsening creates a genuine clinical dilemma: the person is coming off a medication that was at least partially managing their depression in order to try something new, and during the gap, they may feel substantially worse.

A larger dataset from a study of 233 people with treatment-resistant depression who received psilocybin (a pharmaceutical-grade formulation) painted a somewhat more optimistic picture, finding that antidepressant discontinuation was not associated with worsening depression before baseline and did not appear to compromise psilocybin’s efficacy or the quality of the psychedelic experience.⁸ The difference between these findings may come down to sample size, how tapering was managed, or how depression severity was tracked. But both agree on the underlying concern: stopping an antidepressant is not a trivial step, and it should never be done abruptly or without medical guidance.

How Long the Blunting Lasts After Stopping

Even after you stop an SSRI, the blunting of psilocybin’s effects does not disappear overnight. The receptor changes caused by chronic SSRI use take time to reverse. In the same study that documented the 47% weakened-effects rate during SSRI use, researchers also looked at over 1,500 reports from people who had stopped their SSRI or SNRI before taking mushrooms. They found that the probability of reduced effects remained elevated compared to the earliest post-discontinuation timepoint until about three to six months after stopping. A sensitivity analysis that removed fluoxetine (Prozac), which has an unusually long half-life, did not change this result.³

This three-to-six-month window is longer than most people expect. The SSRI itself may be out of your bloodstream within days or a couple of weeks, depending on the specific drug, but the downstream receptor changes persist far beyond that. If you stop an SSRI today and take mushrooms two weeks from now, the psilocybin experience may still be substantially blunted. This finding has real implications for clinical trial design, since a two-week washout period, which some early trials used, may not actually be long enough to get a full psilocybin response.

What About Other Antidepressants

The type of antidepressant matters. As mentioned, bupropion (sold as Wellbutrin) showed a much lower rate of blunting at about 29%, compared to roughly 47% for SSRIs and 55% for SNRIs.³ Bupropion works primarily on dopamine and norepinephrine rather than serotonin, so it does not desensitize 5-HT2A receptors in the same way. For people whose mental health treatment allows flexibility in which antidepressant they take, this is a relevant detail, though switching medications solely to take mushrooms is not something to do casually.

SSRIs also attenuate the effects of MDMA in a comparable way. Studies with citalopram, fluoxetine, and paroxetine all found that SSRIs weakened MDMA’s subjective effects by roughly 30 to 80%, even as plasma levels of MDMA sometimes rose due to the SSRIs’ inhibition of the enzyme CYP2D6.⁹ The point here is broader than mushrooms: if you are on an SSRI, any serotonergic psychedelic or empathogen is likely to hit differently, and usually more weakly, than it would otherwise.

Psilocybin as an Alternative to SSRIs

Part of the reason people ask about this combination is the emerging research on psilocybin as a treatment for depression, which positions it not as a complement to SSRIs but as a potential replacement. A randomized trial published in the New England Journal of Medicine compared psilocybin-assisted therapy with escitalopram (Lexapro) for moderate-to-severe depression over six weeks. About 70% of the psilocybin group met the criteria for a treatment response compared to 48% in the escitalopram group, and 57% in the psilocybin group achieved remission compared to 28% on escitalopram.¹⁰ The primary outcome measure did not reach statistical significance, and the secondary outcomes were not corrected for multiple comparisons, so the trial did not definitively prove psilocybin is better. But the numbers were encouraging enough to fuel a wave of larger follow-up trials.

This research context is important because it shapes how the SSRI-psilocybin interaction question lands for real people. Someone on an SSRI who is interested in psilocybin often has depression, and the implicit question behind “can I take mushrooms on my SSRI?” is frequently “can I try psilocybin therapy without overhauling my entire medication regimen?” Right now, the honest answer is that the SSRI will probably get in the way, and the clinical trials are still working out the best approach to managing that overlap.

What Psilocybin Does and Does Not Share With SSRIs at the Receptor Level

One common misunderstanding is that psilocybin and SSRIs work the same way because they both involve serotonin. They do not. SSRIs prevent the reuptake of serotonin from the synaptic cleft, keeping more of the brain’s own serotonin available for longer. This is a slow, cumulative process that takes weeks to produce noticeable mood changes. Psilocybin, by contrast, is converted to psilocin, which directly activates 5-HT2A receptors. It does not raise serotonin levels the way an SSRI does. It essentially impersonates serotonin at one particular receptor type, triggering a cascade of effects on neural connectivity, sensory processing, and emotional experience that happens within hours, not weeks.

This mechanistic difference is why the two drugs do not amplify each other in a straightforwardly dangerous way. They are acting at different points in the same system. The SSRI has already changed the receptor landscape by the time psilocybin arrives, so psilocybin finds a less responsive audience. Meanwhile, psilocin itself is metabolized through multiple pathways, including UGT enzymes for glucuronidation and with a minor contribution from CYP2D6.¹¹ Some SSRIs, like fluoxetine and paroxetine, are strong inhibitors of CYP2D6, which theoretically could slow psilocin clearance and raise its levels. But since CYP2D6 plays only a small role in psilocin metabolism, this is unlikely to produce a clinically meaningful increase in exposure.

Practical Considerations If You Are on an SSRI

If you are currently prescribed an SSRI and considering psilocybin for any reason, a few things are worth keeping in mind. First, do not stop your SSRI abruptly. Tapering off an antidepressant needs to happen gradually and under medical supervision to minimize withdrawal effects and the risk of a depressive rebound. Second, even after stopping, the blunting of psilocybin effects may persist for months, so a quick washout period is unlikely to give you a “clean” experience. Third, if the goal is therapeutic, the clinical trial infrastructure for psilocybin-assisted therapy is expanding but still limited. Several trials are actively recruiting, and some are specifically studying how to handle the antidepressant-to-psilocybin transition.

For recreational users on SSRIs, the most common outcome is a disappointing trip. Some people respond by taking higher doses of mushrooms to compensate for the blunting, which introduces its own risks: unpredictable responses if the SSRI happens to be less effective that day, difficulty judging potency with different mushroom varieties, and the psychological hazards that come with unexpectedly intense experiences. The safer approach, if a reduced experience is not acceptable, is to work with a prescriber to explore alternatives rather than trying to brute-force through the interaction with a larger dose.

Finally, the distinction between SSRIs and MAOIs deserves emphasis one more time in practical terms. If your antidepressant is an MAOI, the risk profile is fundamentally different and includes the potential for a hypertensive emergency. The reassuring safety data discussed above applies to SSRIs and, to a large extent, SNRIs. It does not extend to MAOIs, where the combination with psilocybin mushrooms has produced at least one documented medical crisis requiring emergency treatment.